New review on advances in endometrial cancer immunotherapy published in Immunotherapy

As published in Immunotherapy. 2026 Mar 18. doi: 10.1080/1750743X.2026.2644799.

Immunotherapy of endometrial cancer: a review of recent advances

• Krešimir Tomić, Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and Herzegovina
• Kristina Katić, Department of Gynecologic Oncology, University Hospital Center Zagreb, Zagreb, Croatia
• Zoran Gatalica, Reference Medicine, Phoenix, Arizona, United States of America
• Gordan Srkalović, University of Michigan Health-Sparrow Herbert-Herman Cancer Center, Lansing, Michigan, United States of America
• Maja Pezer Naletilić, Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and Herzegovina
• Eduard Vrdoljak, Department of Oncology, University Hospital Center Split, Split, Croatia
• Semir Vranić, College of Medicine, QU Health, Qatar University, Doha, Qatar https://orcid.org/0000-0001-9743-7265

Abstract

Immunotherapy with immune checkpoint inhibitors (ICI) has become a transformative pillar in cancer treatment, offering significant improvements in survival and reducing treatment-related side effects compared to traditional therapies. In gynecologic cancers, ICIs have transformed the treatment of endometrial (EC) and cervical cancers, whereas they have not demonstrated clinical benefit in ovarian cancer. This review examines the current state of ICI advancements in EC. Given the unique immunological characteristics of EC, a comprehensive understanding of advancements is crucial for optimizing decision-making and patient outcomes. While ICIs have demonstrated robust and durable efficacy in dMMR/MSI-H EC, the magnitude of benefit in pMMR disease remains modest. Additionally, we examine promising future directions, including personalized immunotherapy approaches and novel combination therapies (e.g. antibody-drug conjugates, PARP inhibitors, antiangiogenic drugs).

Download the manuscript from Taylor & Francis Online.